Form 4: Pfizer Director Echevarria Reports Acquisition of Phantom Stock Units

Director Joseph Echevarria reports acquisition of phantom stock units representing deferred compensation from Pfizer.

Summary

• On March 31, 2025, Joseph Echevarria, a director of Pfizer Inc., acquired 1,825.178 phantom stock units.
• These units represent deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
• The price of the phantom stock units was $25.34.
• Following the transaction, Echevarria directly owns 127,453.425 shares of common stock.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing detailing an insider transaction. It's neutral in tone and reflects routine compensation practices. The sentiment is slightly positive as it indicates continued alignment of the director's interests with the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, providing transparency into the compensation and holdings of Pfizer's directors. It's common for directors to receive deferred compensation in the form of stock or stock units.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding director compensation.

Key Dates

Keywords

Form 4, insider trading, phantom stock units, director compensation, PFE, Pfizer, Echevarria